First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma


Abstract

Purpose: TGFβ signaling plays a key role in tumor progression, including malignant glioma. Small-molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGFβ signaling and reduce tumor progression in preclinical models. To use LY2157299 in the treatment of malignancies, we investigated its properties in a first-in-human dose (FHD) study in patients with cancer.

Experimental Design: Sixty-five patients (58 with glioma) with measurable and progressive malignancies were enrolled. Oral LY2157299 was given as a split dose morning and evening on an intermittent schedule of 14 days on and 14 days off (28-day cycle). LY2157299 monotherapy was studied in dose escalation (part A) first and then evaluated in combination with standard doses of lomustine (part B). Safety was assessed using Common Terminology Criteria for Adverse Events version 3.0, echocardiography/Doppler imaging, serum troponin I, and brain natriuretic peptide (BNP) levels. Antitumor activity was assessed by RECIST and Macdonald criteria.

Results: In part A, 16.6% (5/30) and in part B, 7.7% (2/26) of evaluable patients with glioma had either a complete (CR) or a partial response (PR). In both parts, 15 patients with glioma had stable disease (SD), 5 of whom had SD ≥6 cycles of treatment. Therefore, clinical benefit (CR+PR+SD ≥6 cycles) was observed in 12 of 56 patients with glioma (21.4%). LY2157299 was safe, with no cardiac adverse events.

Conclusions: On the basis of the safety, pharmacokinetics, and antitumor activity in patients with glioma, the intermittent administration of LY2157299 at 300 mg/day is safe for future clinical investigation.

Clinical Cancer Res; 21(3); 553–60. ©2014 AACR.

Introduction

TGFβ ligands (TGFβ1, TGFβ2, TGFβ3), identified in 1980s, are shown to regulate diverse biologic functions (1, 2). All three ligands first engage the specific receptor TGFβRI (3), which then heterodimerizes with TGFβRII. This heterodimer complex phosphorylates the intracellular proteins SMAD2 and SMAD3 activating a signaling cascade to induce several nuclear transduction proteins. With the induction of such proteins the TGFβ signaling pathway influences cellular proliferation, differentiation, motility, survival, and apoptosis in tumor cells. This can promote epithelial–mesenchymal transition (EMT) of a tumor, such as malignant glioma (4). In the microenvironment, TGFβ signaling affects several cell types such as immune cells (5), cancer-initiating cells (6, 7), endothelial cells (8), and fibroblasts (9). The overall effect of these microenvironment changes results in tumor progression and metastasis (10). TGFβ signaling is present in most malignancies (11–14), such as hepatocellular carcinoma (15), pancreatic cancer (16), and myelodysplastic syndromes (17). Because of this prominent role, several small-molecule inhibitors (SMI) have been developed to block the TGFβ signaling pathway with the intention to reduce tumor growth.

SMIs blocking the TGFβ signaling are associated with unique cardiovascular toxicities in animals and these nonmonitorable toxicities have prevented the clinical development of TGFβ inhibitors (18). Like previous TGFβ SMI (18), LY2157299 monohydrate, hereafter referred to as LY2157299, also induces heart valve lesions and aneurysms of the ascending aorta at high doses in animals (19). To predict a safe therapeutic window for a first-in-human dose (FHD) study a preclinical
pharmacokinetic/pharmacodynamic (PK/PD) model was developed (20, 21). After establishing the PK/PD model, LY2157299 was investigated in the FHD study with the objective to characterize its safety, PK, and document its antitumor activity. Because exposure was identified as a main driver for the cardiotoxicity in animals, doses were escalated to a predefined exposure level that was predicted to be safe and efficacious according to the PK/PD model. During the dose escalation, patients were continuously monitored for exposure and safety, which included an integrated cardiac safety evaluation. Using this PK/PD-based safety assessment, the predicted therapeutic window for a safe dose and dose schedule of LY2157299 was confirmed and thus LY2157299 was advanced into phase II clinical investigation.

Materials and Methods

Patients

Eligible patients must have progressed on prior effective therapies and had a histologic or cytologic diagnosis of a malignancy. Starting with cohort 3, only patients with relapsed and progressive glioma were eligible for this study. Before enrollment, investigators determined progression based on clinical symptoms or radiographic progression. All patients were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and were required to have measurable tumor lesions. Starting with cohort 3 onward response was also assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) and were required to have measurable tumor lesions. Patients were required to have adequate hematologic, hepatic, and renal function, and discontinued all previous therapies, including radiotherapy, for cancer at least 4 weeks before study enrolment. Exclusion criteria included medically uncontrolled cardiovascular illness, electrocardiogram anomalies, and serious preexisting medical conditions. Pathologic diagnosis performed at time of first diagnosis was not reassessed by central pathology review in this safety study. Tumor tissue was submitted for assessment of pSMAD2 protein expression and remaining tissue was submitted for genetic mutation evaluation. The details of the biomarker evaluation will be reported elsewhere.

The study was conducted according to the principles of good clinical practice, applicable laws and regulations, and the Declaration of Helsinki. Each institution's review board approved the study and all patients signed an informed consent document before study participation.

IDH1/2 mutation

Where sufficient tumor tissue was available, 287 cancer-related genes were assessed for somatic variants using massive parallel sequencing methods to identify base substitutions, short insertions and deletions, and copy number changes (Foundation Medicine; refs. 23, 24).

Study drug and design

LY2157299 is a serine/threonine kinase inhibitor that blocks specifically the TGFβRI kinase (25). LY2157299 was evaluated in a multicenter open-label, nonrandomized, dose escalation first-in-human phase I study (Fig. 1).

Part A was a dose escalation study. First, patients with advanced or metastatic cancer received daily continuous LY2157299 monotherapy. Then, starting with cohort 3 and for the remainder of the study, patients received LY2157299 on an intermittent dose regimen of 14 days on/14 days off (28-day cycle; ref. 21). The change in dose regimen was prespecified in the protocol depending on the outcome of a 6-month animal toxicology evaluation of the continuous dosing.

Part B was a safety study using LY2157299 on an intermittent dose regimen (14 days on/14 days off = 28-day cycle) at 160 mg/day (80 mg twice daily) and 300 mg/day (150 mg twice daily) in combination with lomustine given once every 6 weeks in patients with recurrent malignant glioma who progressed on effective treatments. Dose escalation was used to ascertain that the PK profile of LY2157299 remained unchanged in the combination with lomustine.

A part C was also conducted to assess different novel tablet formulation. The results of this relative bioavailability (RBA) phase will be reported elsewhere.

Treatment: dose and dose levels

In part A, LY2157299 was given orally twice daily at doses 20 mg (40 mg/day), 40 mg (80 mg/day), 80 mg (160 mg/day), 120 mg (240 mg/day), and 150 mg (300 mg/day) as a tablet in the morning and evening on an empty stomach. No dose adjustments or reductions were allowed and patients were to stop study treatment at any signs of medically significant cardiac toxicity. In part B, patients in cohort 1 received LY2157299 at 160 mg/day on intermittent dosing as defined in part A. Lomustine 100 to 130 mg/m² was given orally once every 6 weeks beginning 1 week after initial LY2157299 dosing. In cohort 2, 300 mg/day LY2157299 was given on intermittent dosing schedule and lomustine as in cohort 1.

Figure 1.

FHD study design: part A, monotherapy and dose escalation. Cohorts 1 and 2 continuous dosing (twice daily, BID) and cohorts 3 to 5 of intermittent dosing (twice daily) on 14-day on and 14-day off cycle (28-day cycle). Part B, combination therapy with lomustine (100 to 150 mg/m²) with >3 patients in each dose group. The combination therapy in two cohorts at 160 mg/day (80 mg twice daily) and 300 mg/day (150 mg twice daily) with LY2157299 given intermittently.
Maximum tolerated dose and dose-limiting toxicity assessment

The maximum-tolerated dose (MTD) was defined as the dose level below which ≥2 patients (of up to 6 patients) experienced a DLT during cycle 1. If DLT were to occur, the previous dose level was to be declared the MTD. Dose escalation to the next cohort proceeded only after: (i) 3 patients completed 1 treatment cycle without a DLT during cycle 1. If DLT were to occur, the previous dose level below which no DLT were observed was declared to be the MTD. Asymptomatic and medically significant cardiotoxicity would have stopped the clinical trial.

Safety assessment

Safety was assessed in patients who received at least one dose of LY2157299 and was based on summaries of adverse events (AE; CTC AE version 3.0), possible relatedness to the study drug (LY2157299 or the combination of LY2157299 + lomustine), DLTs, laboratory changes (including monthly BNP and troponin I levels), changes in ECOG performance status, electrocardiogram (ECG), and echocardiography/Doppler (every 2 cycles and reviewed by a central cardiologist). In addition, standard chemistry, hematology, and urinalysis panels were performed. All concomitant medications were documented throughout the patient's participation in the study.

Efficacy assessment

Radiographic changes (CR, PR, SD, PD) were evaluated by investigators using RECIST 1.0 for all patients and Macdonald Criteria for Adverse Events (CTCAE), version 3.0. Any signs of medically significant cardiotoxicity would have stopped the clinical trial.

Statistical analyses

Patient disposition, demographics, and disease characteristics, safety (including cardiac safety examinations), concomitant medication and response data were summarized by study part, using line plots to investigate trends over time, waterfall plots for change in lesion size based on investigator-reported measurements (using Macdonald criteria), summary statistics or frequencies as appropriate.

Results

FHD study design, patient disposition, and characteristics

Although the FHD study included a RBA part, we here report on the results of 65 patients from 4 investigational sites who participated in parts A and B (design in Fig. 1). Results from patients enrolled in the RBA part will be reported elsewhere. The entire study started in 2006 and was closed in 2012. During this period, the study was on clinical hold for approximately 2 years; the hold was lifted after intermittent dosing in animal toxicology supported the safety of the predicted therapeutic window.

In part A (LY2157299 monotherapy), 39 patients were enrolled; 32 of these patients had glioma. With cohort 5, the predefined maximum exposure level was reached without significant toxicities or DLT. In part B (LY2157299 combined with lomustine), 26 patients received LY2157299 in combination with standard dose of lomustine (15 patients at 160 mg/day and 11 patients at 300 mg/day).

At baseline, the mean age of the patients was 51.8 and 44.5 years in parts A and B, respectively (Table 1). Male patients comprised 76.9% and 73.1% of the population in parts A and B, respectively. Using baseline Eastern Cooperative Oncology Group (ECOG) PS, patients in part A had a better PS than patients in part B. The majority of patients had a primary WHO grade 4 glioma (15/30 or 50% in part A, 20/26 or 76.9% in part B; Table 1).

Glioma patients in part A had a slightly longer length of disease before enrolling in the study compared with part B patients (~22 months compared to 18 months). All but 3 glioma patients (55/58 or 94.8%) had prior surgery, all patients were treated with temozolomide and radiation before their relapse but only approximately 30% were treated with bevacizumab before enrolling into the study. In part A, there were about 20% (6/30) of patients with Table 1. Patient baseline characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Part A n = 39</th>
<th>Part B n = 26</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>Median (range)</td>
<td>Median (range)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>Male 30 (76.9)</td>
<td>19 (73.1)</td>
</tr>
<tr>
<td></td>
<td>Female 9 (23.1)</td>
<td>7 (26.9)</td>
</tr>
<tr>
<td>Origin, n (%)</td>
<td>Caucasian 39 (100)</td>
<td>24 (92.3)</td>
</tr>
<tr>
<td></td>
<td>Hispanic 3 (8)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td></td>
<td>West Asian 1 (3.8)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>ECOG, n (%)</td>
<td>0 15 (38.5)</td>
<td>3 (11.5)</td>
</tr>
<tr>
<td></td>
<td>1 19 (48.7)</td>
<td>17 (65.4)</td>
</tr>
<tr>
<td></td>
<td>2 5 (12.8)</td>
<td>6 (23.1)</td>
</tr>
<tr>
<td>Prior regimens, n (%)</td>
<td>1 17 (43.6)</td>
<td>7 (26.9)</td>
</tr>
<tr>
<td></td>
<td>2 13 (33.3)</td>
<td>11 (42.3)</td>
</tr>
<tr>
<td></td>
<td>3 4 (10.3)</td>
<td>7 (26.9)</td>
</tr>
<tr>
<td></td>
<td>&gt;3 5 (12.8)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Prior radiation, n (%)</td>
<td>1 35 (89.7)</td>
<td>26 (100)</td>
</tr>
<tr>
<td></td>
<td>2 10 (26.3)</td>
<td>26 (100)</td>
</tr>
<tr>
<td>Prior surgery, n (%)</td>
<td>30 (76.9)</td>
<td>25 (96.1)</td>
</tr>
<tr>
<td>Glioma patients only</td>
<td>N = 32</td>
<td>N = 26</td>
</tr>
<tr>
<td>Time from initial diagnosis to before first dose, months</td>
<td>median (range: earliest to most recent)</td>
<td>median (range: earliest to most recent)</td>
</tr>
<tr>
<td></td>
<td>22 (18.0)</td>
<td>26 (100)</td>
</tr>
<tr>
<td>Prior surgery, n (%)</td>
<td>1 32 (100)</td>
<td>26 (100)</td>
</tr>
<tr>
<td>Prior bevacizumab, n (%)</td>
<td>1 10 (31.3)</td>
<td>7 (26.9)</td>
</tr>
<tr>
<td>Prior temozolomide and radiation, n (%)</td>
<td>32 (100)</td>
<td>26 (100)</td>
</tr>
<tr>
<td>Glioma WHO, n (%) at study entry</td>
<td>n = 30*</td>
<td>n = 26</td>
</tr>
<tr>
<td>Grade 1</td>
<td>1 (3.3)</td>
<td>—</td>
</tr>
<tr>
<td>Grade 2</td>
<td>2 (6.7)</td>
<td>—</td>
</tr>
<tr>
<td>Grade 3</td>
<td>6 (20)</td>
<td>4 (15.4)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>21 (70)</td>
<td>22 (84.6)</td>
</tr>
<tr>
<td>Secondary grade 4</td>
<td>6 (20)</td>
<td>2 (7.7)</td>
</tr>
<tr>
<td>Primary grade 4</td>
<td>15 (50)</td>
<td>20 (76.9)</td>
</tr>
</tbody>
</table>

Data on grade not available for 2 patients in cohort 3.
secondary grade 4 glioma and 30% (9/30) had low-grade glioma (WHO grade 1–3). Tissue was available in 21 patients (11 in part A and 10 in part B), 5 of whom had IDH1/2 mutation (5/21; 23.8%).

At study closure in 2012 in part A, 33 patients (33/39; 84.6%) discontinued the study treatment due to progressive disease, one patient died during treatment as the tumor progressed, and 3 patients withdrew from the study (Table 2). In part B, 22 patients (22/26; 84.6%) discontinued due to progressive disease, one patient died during treatment due to his cancer, and one withdrew from the study. As of June 2014, 3 patients were still receiving LY2157299 (R42, treated for 3.7 years, and R44, treated for 48 cycles or 3.7 years).

### Safety measures (including integrated cardiac monitoring results)

Although some possible drug-related toxicities were observed in this study, there was no cluster of serious adverse events or (AE) as determined by CTCAE v.3 grading (Table 3). No definitive drug-related toxicity or DLT was reported in either of the two study parts.

In part A, three patients (7.7%) had four grade 3/4 toxicities that were considered possibly drug related. One such patient experienced a grade 4 thrombocytopenia that was considered a possible DLT. This patient recovered from the serious AE (SAE) but later died due to tumor progression. The second patient discontinued the study due to ischemic stroke (grade 4) after surgical resection of his tumor during the off-period of LY2157299 treatment. The third patient experienced grade 4 pulmonary embolism and dyspnea, and after hospitalization died of disease, such as pain medication. The most common concomitant drugs in both parts of the study were as follows: dexamethasone (60.0% part A, 84.6% part B), omeprazole (56.4% part A, 50.0% part B), levetiracetam (43.6% part A, 84.6% part B), and acetaminophen (41.0% part A, 34.6% part B).

### Efficacy measures

**Radiographic responses based on Macdonald criteria in parts A and B for patients with glioma.** In part A, there were 33.3% (13/39) deaths that occurred on treatment or during follow-up and were related to tumor progression. Baseline measurements according to the Macdonald method were available for 26 of 30 patients and radiographic responses were assessed in 24 patients (Fig. 2A). Of the 30 patients with glioma, overall response rate was 16.6% (5/30), including 7 CRs (2/30, 6.6%) and 3 PRs (3/30, 10%; Table 2). These responses were assessed on the basis of measurable lesions. Ten patients (10/30; 33.3%) had stable disease (SD). The rate of clinical benefit (CR+PR+SD ≥ 6 cycles) was 20% (6/30). In part B, there were 57.7% (15/26) deaths on or during follow-up and all related to tumor progression. Baseline measurements according to Macdonald were available for 18 of 26 patients, of whom only 12 were evaluated for radiographic response (Fig. 2B).
Duration of treatment by number of cycles is presented in Fig. 2C for part A. On average, patients received 2 cycles of treatment and a subgroup of patients was treated beyond cycle 6 (Table 2; Fig. 2C). The duration of treatment by number of cycles is presented in Fig. 2D. Two patients (2/26; 7.7%) had PR; one of these patients had a possible CR (patient R62). A clinical benefit response (CR + PR + SD/C21 6 cycles) rate of 23.1% (6/26) was observed (Table 2).

The clinical responders had an initial disease stabilization followed by radiographic tumor lesion reduction (Fig. 3A–C). The radiographic responses were not dependent on tumor size before initiation of treatment (Fig. 3A). One patient (R19) had a complete response in cycle 28, which was confirmed in cycle 32. Another patient had first a pseudoprogression with no clinical progression (part A, patient R21) and then had a marked radiographic response. The remaining patients had a gradual reduction of their tumor. In 2 of these patients, a CR developed and is still being observed after at least 3 years of treatment (Fig. 3B).

Tumor characteristics and clinical response. In part A, 50% (15/30) of patients had either low-grade glioma (9/30) or secondary glioblastoma (6/30), and 50% (15/30) had primary glioblastoma (Table 1). In low-grade glioma or secondary glioblastoma, 20% (3/15) of patients showed tumor response (CR/PR) and a similar response rate (13.3%, 2/15) was observed in patients with primary glioblastoma (Data not shown). In part B, there were fewer patients with low-grade glioma or secondary glioblastoma (23.1%, 6/26) compared with part A, and more patients with...
primary glioblastoma (76.9%, 20/26; Table 1). Responses (CR/PR) were observed in 33.3% (2/6) of patients with low grade glioma or secondary glioblastoma and SD/C21 cycles (3/20; 15%) were observed only in patients with primary glioblastoma (data not shown). There were 5 of 21 patients with IDH1/2 mutations (Table 1). A clinical benefit (CR/PR/C21 SD 6 cycles) was observed in 4 of the 5 patients (80%; 4/5—two in each parts of the study; data not shown).

Discussion

In the current study, we show that the novel SMI LY2157299 targeting TGFβ signaling can be safely administered and has a clinical benefit in a tumor type where this pathway is considered a key driver of progression. The favorable toxicity profile of LY2157299 included no medically significant cardiovascular toxicities as monitored by monthly serial plasma markers (troponin I, BNP) and echocardiography/Doppler imaging every 2 months. Contrary to the concern that blocking the TGFβ signaling pathway may potentially induce secondary malignancies (26), no signs of tumorigenesis were observed, including in patients who have been in treatment longer than 3 years. With the exception of diarrhea (grade 2) which presented in one patient during each of the 14-day on-treatment periods and two cases of grade 3/4 thrombocytopenia, no other events were judged to be possibly related to LY2157299 treatment. The causes for both cases of thrombocytopenia remain unclear, because LY2157299 has shown no direct bone marrow toxicity in animal studies or in human in vitro bone marrow assays. Both patients had previous bevacizumab treatment and had shown moderate platelet reduction during bevacizumab treatment. Perhaps in both patients the previous antibody treatment unmasked an underlying idiopathic thrombocytopenia (ITP), which is thought to be suppressed by regulatory T cells (27). As LY2157299 is designed to block TGFβ production including in regulatory T cells, its administration may have removed the regulatory T cell–mediated suppression of ITP.

LY2157299 treatment showed single-agent activity in glioma patients who had progressed on previous treatments not only based on radiographic responses, but also by SD exceeding 5 cycles (SD/C21 6 cycles, which is ~5 months). In part A, there was 1 patient and in part B there were 4 patients who had such a prolonged tumor growth control (Fig. 2C and D). The radiographic response
often occurred after several cycles. Whether this pattern of response is similar to the one observed for ipilimumab in melanoma awaits further investigation (28). Similar to ipilimumab, LY2157299 may cause an activation of cytotoxic T cells by blocking the TGFβ signaling in T regulatory cells. Furthermore, the combination of LY2157299 and lomustine was justified because of its additive in vitro and in vivo effects (29). In two patients of part B, a tumor response was observed requiring a formal comparative phase II study to determine whether the combination is more active than the monotherapy. This phase II study recently completed enrollment and awaits study results (30).

The responses are also reminiscent of those reported for glioma patients treated with trabedersen, an antisense oligonucleotide targeting TGFβ2 (31). Similar to trabedersen, the responses appeared to be more common in patients with lower WHO grade glioma. Secondary or lower grade gliomas are commonly associated with IDH1 mutations (23), and IDH1 mutations have been recently associated with TGFβ signaling (32, 33). To further investigate this possibility, we assessed the IDH1/2 mutation in tumor tissue of the original diagnostic specimen. Given the limited amount of tissue available, it was not possible to assess the methylation status of the MGMT promoter status in the same patient group. Thus, it is not possible to determine whether MGMT promoter status also plays a role in determining patients with a possible response to LY2157299. Among the 5 patients with an IDH1/2-mutated tumor, 4 patients had either CR/PR or SD ≥ 6 cycles (4/5; 80%). Among the 11 patients with CR/PR/SD ≥ 6 cycles and compared with these 4 patients with IDH1/2 mutation (4/11; 36.3%), there were 7 other patients who did not have the IDH1/2 mutation (7/11; 63.6%). This observation suggests that the TGFβ signaling pathway may be enriched in the IDH1/2-mutated tumors, but also be present in other less molecularly characterized glioma, perhaps those with a mesenchymal phenotype (34). Therefore, future clinical studies with LY2157299 will likely benefit from a patient selection based on profiling tumors for a TGFβ-dependent signature.

In summary, LY2157299 has predictable pharmacokinetics and a favorable safety profile to continue its clinical investigation in phase II, and has shown clinical benefit at the recommended dose predicted by a preclinical PK/PD model.

**Disclosure of Potential Conflicts of Interest**

N.S. Pillay is an employee of and has ownership interest (including patents) in Eli Lilly and Co. D. Desaiah and M.M. Lahn are employees of Eli Lilly and Co. L. Paz-Ares has speakers bureau honoraria from Eli Lilly and Co. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**

**Conception and design:** J. Rodon, M.A. Carducci, I. Guergouieva, A.L. Cleverly, N.S. Pillay, M.M. Lahn, J. Baselga  
**Development of methodology:** J. Rodon, E. Calvo, J. Seoane, I. Guergouieva, N.S. Pillay, J. Blakeley, M.M. Lahn, J. Baselga  
**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** J. Rodon, M.A. Carducci, J.M. Sepulveda-Sanchez, E. Calvo, J. Seoane, I. Braia, E. Sicart, N.S. Pillay, S.T. Estrem, J. Blakeley, M.M. Lahn, J. Baselga  
**Writing, review, and/or revision of the manuscript:** J. Rodon, M.A. Carducci, J.M. Sepulveda Sanchez, A. Azaro, E. Calvo, J. Seoane, I. Braia, E. Sicart, A.L. Cleverly, N.S. Pillay, D. Desaiah, S.T. Estrem, L. Paz-Ares, M. Holdhoff, J. Blakeley, M.M. Lahn, J. Baselga  
**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** N.S. Pillay, M.M. Lahn  
**Study supervision:** J. Rodon, M.A. Carducci, E. Calvo, I. Guergouieva, N.S. Pillay, L. Paz-Ares, M.M. Lahn  
**Other (study conduct):** A. Azaro, M.M. Lahn

**Acknowledgments**

The authors thank patients for their willingness to participate in this study. The authors also thank all site staff at the four institutions and the trial personnel at Eli Lilly and Company, Quintiles, and ICON.

**Grant Support**

This study was supported by Eli Lilly and Company. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement/ in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 31, 2014; revised October 20, 2014; accepted November 3, 2014; published OnlineFirst November 25, 2014.
Rodon et al.


